ClinicalTrials.gg
RecruitingNCT06694051Updated Nov 19, 2024

Application of Phototherapeutic Keratectomy Mode to Mark the Axis of Astigmatism

An interventional study of marking in Astigmatism, sponsored by Tianjin Eye Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Tianjin Eye Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Corneal refractive surgery is an effective way to correct refractive error. Modern corneal refractive surgery for the correction of myopia or hyperopia can achieve or close to the expected goal, but to eliminate astigmatism is always one of the major problems of corneal refractive surgery. The key point in the correction of astigmatism is that as a vector parameter, astigmatism has both magnitude and direction. The angle error may be caused by the rotation of the patient's head position and the involuntary rotation of eyes. Phototherapeutic keratectomy can precisely cut the corneal tissue, and is often used in clinic to remove corneal scars or repair corneal surface morphology. In this study, the excimer laser therapeutic keratectomy mode was used to achieve accurate marking of the axis of astigmatism by setting the treatment laser parameters. With the help of the static cyclotorsion of the eye, the precise treatment of astigmatism could realize.

02

Conditions studied

  • Astigmatism

Browse trials for

03

In context

Astigmatism

420 studies on the registry are indexed under Astigmatism; 54 are open to participants now.

This study's planned enrollment of 100 is above the median of 56 across 328 interventional studies indexed under Astigmatism.

Browse Astigmatism studies →

Lead sponsor

Tianjin Eye Hospital is the lead sponsor of 52 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 18 years old

Exclusion criteria

Exclusion Criteria:

  • ocular disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    ptk-group

    Procedure: marking

  • No intervention
    limbus-group

Interventions

  • Proceduremarking

    axis marking

06

What researchers measure

Primary outcomes

  1. refraction

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Tianjin Eye Hospital
    Tianjin, Tianjin Municipality 300020, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06694051
Lead sponsor
Tianjin Eye Hospital
Responsible party
Sponsor
First posted
Nov 19, 2024
Start date
Oct 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Nov 19, 2024

Study contacts

Wang
Contact
jiamei3536@163.com
+86 022 27313336

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion